Drug Trial Radar · NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
258
Planned (sponsor's estimate)
Start
Jan 25, 2021
Primary completion
Sep 13, 2027
Study completion Apr 20, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
Conditions
- Plasma Cell Myeloma Refractory
Interventions
IsatuximabDrug
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
DexamethasoneDrug
Pharmaceutical form: Tablet; Route of administration: Oral
PomalidomideDrug
Pharmaceutical form: Capsule; Route of administration: Oral
Belantamab mafodotinDrug
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
PegenzileukinDrug
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
SAR439459Drug
Pharmaceutical form: Solution for injection; Route of administration: Intravenous
BelumosudilDrug
Pharmaceutical form: tablet; route of administration: oral
EvorpaceptDrug
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximabTime frame: Through the end of cycle 1 (approximately 6 weeks)
- Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)Time frame: Up to approximately 28 months after the First patient in or scheduled assessment
- Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudiesTime frame: Up to approximately 28 months after the First patient in or scheduled assessment
Locations
28 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- Site Number : 8400001
Birmingham, Alabama · Completed
Winship Cancer Institute of Emory University- Site Number : 8400010
Atlanta, Georgia · Recruiting
University of Illinois-Chicago - College of Medicine- Site Number : 8400007
Chicago, Illinois · Completed
University of Michigan Health System - Ann Arbor- Site Number : 8400004
Ann Arbor, Michigan · Recruiting
Roswell Park Cancer Institute- Site Number : 8400008
Buffalo, New York · Recruiting
The Ohio State University- Site Number : 8400012
Columbus, Ohio · Recruiting
Investigational Site Number : 0360006
Wollongong, New South Wales, Australia · Recruiting
Investigational Site Number : 0360003
Heidelberg, Victoria, Australia · Completed
Investigational Site Number : 0360002
Melbourne, Victoria, Australia · Recruiting
Investigational Site Number : 0360001
Richmond, Victoria, Australia · Recruiting
Investigational Site Number : 2500002
Lille, France · Recruiting
Investigational Site Number : 2500001
Nantes, France · Recruiting
Investigational Site Number : 2500003
Paris, France · Recruiting
Investigational Site Number : 2500004
Paris, France · Recruiting
Investigational Site Number : 2760006
Frankfurt, Germany · Recruiting
Investigational Site Number : 2760008
Lübeck, Germany · Recruiting
Investigational Site Number : 3000002
Athens, Greece · Recruiting
Investigational Site Number : 3000001
Athens, Greece · Recruiting
Investigational Site Number : 3760002
Jerusalem, Israel · Recruiting
Investigational Site Number : 3760003
Ramat Gan, Israel · Recruiting
Investigational Site Number : 3760001
Tel Aviv, Israel · Recruiting
Investigational Site Number : 3800001
Meldola, Reggio Emilia, Italy · Recruiting
Investigational Site Number : 5780001
Oslo, Norway · Recruiting
Puerto Rico Medical Research Center- Site Number : 8400005
Hato Rey, Puerto Rico, Puerto Rico · Completed
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, South Korea · Recruiting
Investigational Site Number : 4100004
Seoul, Seoul-teukbyeolsi, South Korea · Recruiting
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, South Korea · Recruiting
Investigational Site Number : 4100003
Seoul, Seoul-teukbyeolsi, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.